Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U3EP
|
|||
| Former ID |
DCL000234
|
|||
| Drug Name |
Resveratrol
|
|||
| Synonyms |
Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Giant cell arteritis [ICD-11: 4A44.2; ICD-10: M31.5, M31.6] | Phase 3 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 3 | [1] | ||
| Systemic sclerosis [ICD-11: 4A42; ICD-9: 710.1] | Phase 3 | [1], [2] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Discontinued in Phase 2 | [3] | ||
| Company |
Sirtris Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12O3
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
|
|||
| InChI |
1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
|
|||
| InChIKey |
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
|
|||
| CAS Number |
CAS 501-36-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6374, 458391, 584207, 611168, 837578, 855986, 866574, 7890614, 8145576, 10299643, 10321586, 11537676, 12015089, 14822845, 17388746, 17405667, 22388006, 24278055, 24715042, 24860876, 26512266, 26612338, 26679661, 26697115, 26736772, 26747076, 26747077, 26751586, 26751587, 26759440, 29204531, 36887952, 46386962, 46493745, 46504705, 47291249, 47515445, 47589112, 47959898, 48035263, 48035264, 48185110, 48185111, 48334633, 48424038, 48425593, 49661756, 49698529, 49734167, 49833229
|
|||
| ChEBI ID |
CHEBI:45713
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Adlercreutzia equolifaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Resulting Metabolite | Dihydroresveratrol | |||
| Description | Trans-resveratrol can be metabolized to Dihydroresveratrol by Adlercreutzia equolifaciens. | |||
|
Studied Microbe: Slackia equolifaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Resulting Metabolite | Dihydroresveratrol | |||
| Description | Trans-resveratrol can be metabolized to Dihydroresveratrol by Slackia equolifaciens. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4] | |||
| Resulting Metabolite | 3,4'-dihydroxy-trans-stilbene; 3,4'-dihydroxybibenzyl | |||
| Description | Trans-resveratrol can be metabolized to 3,4'-dihydroxy-trans-stilbene and 3,4'-dihydroxybibenzyl by gut microbiota. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Rat | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Bacteroides was decreased by Resveratrol (p < 0.01). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Kunming mice | Experimental Sample | Colonic content | |
| Disease or Condition | High fat induced obesity | |||
| Description | The abundance of Bifidobacterium was increased by Resveratrol. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfovibrionales | ||||
|
Studied Microbe: Desulfovibrionaceae
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Rat | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Desulfovibrionaceae was decreased by Resveratrol (p < 0.01). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Rat | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Blautia was increased by Resveratrol (p < 0.05). | |||
|
Studied Microbe: Dorea
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Rat | Experimental Sample | Faeces | |
| Disease or Condition | High fat diet | |||
| Description | The abundance of Dorea was increased by Resveratrol (p < 0.01). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Colitis | |||
| Description | The abundance of Ruminococcus gnavus was increased by Resveratrol (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus faecalis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Kunming mice | Experimental Sample | Colonic content | |
| Disease or Condition | High fat induced obesity | |||
| Description | The abundance of Enterococcus faecalis was decreased by Resveratrol. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Kunming mice | Experimental Sample | Colonic content | |
| Disease or Condition | High fat induced obesity | |||
| Description | The abundance of Lactobacillus was increased by Resveratrol. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[8] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Kunming mice | Experimental Sample | Colonic content | |
| Disease or Condition | High fat induced obesity | |||
| Description | The abundance of Akkermansia was increased by Resveratrol. | |||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Colitis | |||
| Description | The abundance of Akkermansia muciniphila was increased by Resveratrol (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Firmicutes/Bacteroidetes ratio
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Kunming mice | Experimental Sample | Colonic content | |
| Disease or Condition | High fat induced obesity | |||
| Description | The abundance of Firmicutes/Bacteroidetes ratio was decreased by Resveratrol. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018787) | |||
| REF 4 | In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr. 2013 Feb;97(2):295-309. | |||
| REF 5 | Sinapic acid and resveratrol alleviate oxidative stress with modulation of gut microbiota in high-fat diet-fed rats. Food Res Int. 2019 Feb;116:1202-1211. | |||
| REF 6 | Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct. 2014 Jun;5(6):1241-9. | |||
| REF 7 | Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J Leukoc Biol. 2019 Aug;106(2):467-480. | |||
| REF 8 | Resveratrol and the Interaction between Gut Microbiota and Arterial Remodelling. Nutrients. 2020 Jan 1;12(1):119. | |||
| REF 9 | Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. | |||
| REF 10 | Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.